2004/128/EC: Commission Decision of 23 January 2004 on financial assistance from the Community for the storage of antigens for production of foot-and-mouth disease vaccines in France, Italy and the United Kingdom in 2004 (Text with EEA relevance) (notified under document number C(2004) 102)
Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗
1. The Community shall grant financial assistance to Agence Française de Securité Sanitaire des Aliments for the stocking of antigens for the production of foot-and-mouth disease vaccines at the premises of Agence Française de Securité Sanitaire des Aliments, Lyon. 2. For the period from 1 January to 31 December 2004 the maximum amount of financial assistance shall be EUR 30000.
1. The Community shall grant financial assistance to Istituto Zooprofilattico Sperimentale di Brescia for the stocking of antigens for the production of foot-and-mouth disease vaccines at the premises of Istituto Zooprofilattico Sperimentale di Brescia. 2. For the period from 1 January to 31 December 2004 the maximum amount of financial assistance shall be EUR 30000.
1. The Community shall grant financial assistance to Merial S.A.S. with its headquarters in Lyon, France, for the stocking of antigens for the production of foot-and-mouth disease vaccines at the premises of Merial S.A.S., Lyon, France, and at the premises of Merial S.A.S., Pirbright, United Kingdom. 2. For the period from 1 January to 31 December 2004 the maximum amount of financial assistance shall be EUR 81047.
1. The Community's financial assistance referred to in Article 1(2), Article 2(2) and Article 3(2) shall only be granted if the conditions provided for in Article 4 of Decision 91/666/EEC are complied with and the information and documents provided for in paragraph 2 are submitted to the Commission by 28 February 2005 at the latest. 2. The information and documents referred to in paragraph 1 shall include the following: (a) technical information on: (i) the amount and type of antigen stored (storage records), (ii) storage equipment used (type, number and capacity of tanks), (iii) security systems in place (temperature control, anti-theft measures), (iv) insurance arrangements (fire, accidents); (b) financial information (completion of a form based on the model set out in the Annex).
This Decision is addressed to the Agence Française de Securité Sanitaire des Aliments, 31, avenue Tony Garnier, BP 7033, F-69342 Lyon Cedex 07, France, Istituto Zooprofilattico Sperimentale di Brescia, Via Bianchi 9, I-25124 Brescia, Italy, and Merial S.A.S., 29, avenue Tony Garnier, BP 7123, F-69002 Lyon Cedex 07, France. Done at Brussels, 23 January 2004. For the Commission David Byrne Member of the Commission (1) OJ L 224, 18.8.1990, p. 19. Decision as last amended by Regulation (EC) No 806/2003 (OJ L 122, 16.5.2003, p. 1). (2) OJ L 368, 31.12.1991, p. 21. (3) OJ L 33, 8.2.2000, p. 19.
Financial information related to the storage of antigens for production of foot-and-mouth disease vaccines >PIC FILE= "L_2004037EN.002602.TIF">
Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.